BR112017017643A2 - formulação farmacêutica tópica - Google Patents

formulação farmacêutica tópica

Info

Publication number
BR112017017643A2
BR112017017643A2 BR112017017643A BR112017017643A BR112017017643A2 BR 112017017643 A2 BR112017017643 A2 BR 112017017643A2 BR 112017017643 A BR112017017643 A BR 112017017643A BR 112017017643 A BR112017017643 A BR 112017017643A BR 112017017643 A2 BR112017017643 A2 BR 112017017643A2
Authority
BR
Brazil
Prior art keywords
composition
carrier system
residual carrier
pharmaceutical formulation
nsaid
Prior art date
Application number
BR112017017643A
Other languages
English (en)
Inventor
Davis Adrian
Original Assignee
Futura Medical Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futura Medical Developments Ltd filed Critical Futura Medical Developments Ltd
Publication of BR112017017643A2 publication Critical patent/BR112017017643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

é descrita aqui uma composição tópica para aplicação de um nsaid, a composição compreendendo uma solução ou suspensão do nsaid como ingrediente ativo em um sistema carreador residual compreendendo um poliálcool, um éter glicol, um éster de um ácido graxo maior e água, e os ingredientes do sistema carreador residual têm as seguintes concentrações em porcentagens por peso: poliálcool 50 ? 90%; éter glicol 7,5 ? 40%; éster 0,5 ? 5%; e água até 10%. ou a composição ou o sistema carreador residual é uma única fase a condições ambiente. a composição pode também compreender um solvente volátil tal como etanol ou álcool isopropílico.
BR112017017643A 2015-02-20 2016-02-22 formulação farmacêutica tópica BR112017017643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502845A GB201502845D0 (en) 2015-02-20 2015-02-20 Topical pharmaceutical formulation
PCT/GB2016/050444 WO2016132159A1 (en) 2015-02-20 2016-02-22 Topical pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BR112017017643A2 true BR112017017643A2 (pt) 2018-05-08

Family

ID=52821910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017643A BR112017017643A2 (pt) 2015-02-20 2016-02-22 formulação farmacêutica tópica

Country Status (8)

Country Link
US (1) US10028927B2 (pt)
EP (1) EP3258912A1 (pt)
JP (1) JP2018505905A (pt)
CN (1) CN107249573A (pt)
BR (1) BR112017017643A2 (pt)
GB (1) GB201502845D0 (pt)
RU (1) RU2017129893A (pt)
WO (1) WO2016132159A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609968D0 (en) 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
CN111432802A (zh) * 2017-12-04 2020-07-17 强生消费者公司 含有非甾体抗炎药的局部用乳液组合物
JP2022544846A (ja) * 2019-08-21 2022-10-21 ティンバー ファーマシューティカルズ， インコーポレイテッド 活性剤を局所的に送達するための溶媒送達システム
GB2596286B (en) 2020-06-20 2023-01-25 Francis Davis Adrian Adherence to topical therapy
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039561A1 (en) * 1995-11-15 2002-04-04 Doughty Darrell Gene Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
GB9902227D0 (en) 1999-02-01 1999-03-24 Cipla Limited Pharmaceutical composition for topical administration
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US20050137164A1 (en) 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
US20050244522A1 (en) * 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
GB0921686D0 (en) 2009-12-11 2010-01-27 Reckitt Benckiser Healthcare I Topical formulation

Also Published As

Publication number Publication date
US20180036269A1 (en) 2018-02-08
WO2016132159A1 (en) 2016-08-25
EP3258912A1 (en) 2017-12-27
RU2017129893A3 (pt) 2019-08-12
US10028927B2 (en) 2018-07-24
GB201502845D0 (en) 2015-04-08
JP2018505905A (ja) 2018-03-01
RU2017129893A (ru) 2019-03-20
CN107249573A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
BR112017017643A2 (pt) formulação farmacêutica tópica
CR20140391A (es) Composiciones topicas que comprenden fipronilo y permetrina y sus metodos de uso
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CO6220926A2 (es) Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid)
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112016002915A2 (pt) formulação agroquímica pulverizável, formulação concentrada, uso de um éster graxo de um poliol c3 a c8, ou oligômero do mesmo, e, métodos para reduzir o desvio de pulverização e para tratamento de vegetação para controlar pestes e/ou fornecer nutrientes
CA2864118A1 (en) Formulations of bendamustine
AR071533A1 (es) Microemulsion mejorada con un amplio rango de aplicacion
BR112016003446A8 (pt) limitador de corrente de curto-circuito de rápida comutação e sistema limitador de corrente
BR112013020167A2 (pt) melhoradores de permeação para formulações tópicas
BR112014016550A2 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112015020707A2 (pt) formulações transdermicas
EA201791166A1 (ru) Препараты с контролируемым высвобождением
RS54131B1 (en) NEW PHARMACEUTICAL FORMULATION FOR FUNGAL INFECTION TREATMENT
NI201900063A (es) Amidas aromáticas de ácido carboxílico
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
BR112018070626A2 (pt) formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição
BR112013010714A2 (pt) Composição farmacêutica e uso de um composto antibiótico
TR201820773A2 (tr) Kararli su/yağ fazi di̇spersi̇yonlarina sahi̇p dekspantenol i̇çeren krem formülasyonu
TH154049A (th) องค์ประกอบสำหรับใช้เฉพาะที่ซึ่งประกอบรวมด้วยไฟโพรนิลและเพอร์เมธรินและวิธีใช้
CO2018000525A2 (es) Concentrado que contiene alprostadil
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат
BR112016013172A2 (pt) Formulações agroquímicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]